V
VAXCYTE INC
NASDAQ: PCVX (Vaxcyte, Inc.)
Kemas kini terakhir: 2 hari lalu, 9:47PM53.57
0.75 (1.42%)
| Penutupan Terdahulu | 52.82 |
| Buka | 55.37 |
| Jumlah Dagangan | 5,179,983 |
| Purata Dagangan (3B) | 1,326,701 |
| Modal Pasaran | 7,012,648,448 |
| Harga / Buku (P/B) | 2.27 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Nov 2025 |
| EPS Cair (TTM) | -3.99 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.72% |
| Nisbah Semasa (MRQ) | 17.70 |
| Aliran Tunai Operasi (OCF TTM) | -459.78 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -419.13 M |
| Pulangan Atas Aset (ROA TTM) | -14.53% |
| Pulangan Atas Ekuiti (ROE TTM) | -19.66% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Vaxcyte, Inc. | Menaik | Menurun |
AISkor Stockmoo
1.8
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | 2.0 |
| Purata | 1.75 |
|
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.68% |
| % Dimiliki oleh Institusi | 117.40% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Paradigm Biocapital Advisors Lp | 30 Sep 2025 | 3,784,755 |
| Julat 52 Minggu | ||
| Median | 85.00 (58.67%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| BTIG | 10 Nov 2025 | 85.00 (58.67%) | Beli | 42.92 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |